Skip to content
Menu

Amneal Pharmaceuticals, Inc. AMRX

Full chart Compare
Set alert

Price alert · AMRX

All alert types
21.12 USD -0.27 (-1.26%)

Regular-session close

21.78 +0.66 +3.15%

After hours · Nov 20, 6:11 PM ET

21.07 Day range 21.70
11.52 52-week range 21.88
YTD
+67.62%
1 year
+83.33%

5D -0.38 (-1.77%)

2121.5022WedThuFriMonTue21.12
Market cap
7.36B
Revenue (ttm)
3.20B
Profit margin
4.17%
EPS (ttm)
0.40
Shares out
348.41M
P/E ratio
52.80
Forward P/E
17.13
YTD return
+67.62%
1-year return
+83.33%
50-day average
20.05
Volume
1.67M
Avg volume
3.16M
Open
21.25
Previous close
21.39
Day's range
21.07 – 21.70
52-week range
11.52 – 21.88
Beta
1.21
Analysts
Strong Buy
Price target
24.29 (+15.0%)
Earnings date
Feb 26, 2027

Key statistics

200-day average
16.25
Enterprise value
10.68B
PEG ratio
2.08
Price / sales
2.30
Price / book
13.85
Revenue growth
10.00%
Free cash flow
-45.13M
Total cash
162.21M
Total debt
3.28B
Return on equity
70.00%
Short % of float
4.64%

Fundamental scorecard

8 of 25 checks passed on AMRX’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 0 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AMRX Revenue — quarterly 862.68M
AMRX Net income — quarterly -21.70M
AMRX EPS — quarterly -0.06

Earnings

AMRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 26, 2027Dec 30, 20260.24———
Nov 3, 2026Sep 30, 20260.23740.26+0.02+9.52%
Jul 30, 2026Jun 30, 20260.22250.30+0.08+34.83%
May 7, 2026Mar 31, 20260.170.27+0.10+58.82%
Feb 27, 2026Dec 31, 20250.180.21+0.03+16.67%
Oct 30, 2025Sep 30, 20250.130.17+0.04+30.77%

Upgrades / downgrades

AMRX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026Leerink PartnersmainOutperformOutperform
Nov 4, 2026JP MorganmainOverweightOverweight
Oct 22, 2026JP MorganmainOverweightOverweight
Sep 23, 2026Oppenheimerinit—Outperform
Sep 17, 2026BarclaysmainOverweightOverweight
Sep 9, 2026Leerink Partnersinit—Outperform

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
amneal.com

News

Your note

Sign in to keep a note on AMRX — it syncs with the Stock Master app.

Insider holders

AMRX insider holders
InsiderRelationLatest transactionDateShares held
GEORGE JEFFREY P.DirectorConversion of Exercise of derivative securityMay 6, 2026344,614
KONIDARIS TASOSChief Financial OfficerConversion of Exercise of derivative securityMar 3, 2026449,434
MEISTER PAUL MDirectorConversion of Exercise of derivative securityMay 6, 2026832,800
NARK THEODORE C.DirectorConversion of Exercise of derivative securityMay 6, 2026325,848
PATEL CHINTUChief Executive OfficerStock Award(Grant)Aug 9, 20260
PATEL CHIRAG KChief Executive OfficerStock Award(Grant)Aug 9, 20260

Institution ownership

AMRX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.77%26,877,188567.51MSep 29, 2026
Vanguard Portfolio Management LLC4.03%12,365,663261.10MSep 29, 2026
TPG GP A, LLC4.02%12,328,767260.32MSep 29, 2026
Rubric Capital Management LP2.78%8,536,755180.25MSep 29, 2026
Vanguard Capital Management LLC2.61%7,987,664168.66MSep 29, 2026
State Street Corporation2.44%7,471,033157.75MSep 29, 2026

Fund ownership

AMRX fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF3.59%10,992,537232.11MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.81%5,555,668117.31MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.31%4,029,12585.07MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.31%4,020,77284.90MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund0.83%2,549,07753.82MJun 29, 2026
Invesco Exchange-Traded Fund Trust-Invesco S&P SmallCap Momentum ETF0.68%2,084,52844.01MSep 29, 2026